TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from China Touyun Tech Group ( (HK:1332) ).
Touyun Biotech Group Limited has released supplemental information related to the remuneration of its CEO, Ms. Amy Ha, for the years 2022 and 2023. The announcement highlights a significant decrease in her remuneration from HK$3,102,000 in 2022 to HK$16,000 in 2023, which may indicate a strategic financial adjustment within the company.
The most recent analyst rating on (HK:1332) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Touyun Tech Group stock, see the HK:1332 Stock Forecast page.
More about China Touyun Tech Group
Touyun Biotech Group Limited, incorporated in Bermuda, operates in the biotech industry. The company, along with its subsidiaries, focuses on developing and providing biotechnology solutions.
Average Trading Volume: 3,198,906
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.07B
For a thorough assessment of 1332 stock, go to TipRanks’ Stock Analysis page.